These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 26687480)

  • 1. Vitamin C as Cancer Destroyer, Investigating Sulfhydration, and the Variability in CFTR Interactome.
    Chem Biol; 2015 Dec; 22(12):1575-6. PubMed ID: 26687480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CANCER. Revisiting vitamin C and cancer.
    Reczek CR; Chandel NS
    Science; 2015 Dec; 350(6266):1317-8. PubMed ID: 26659042
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-cancer effects of vitamin C revisited.
    van der Reest J; Gottlieb E
    Cell Res; 2016 Mar; 26(3):269-70. PubMed ID: 26768769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acta Oncologica and a new generation of scientists in oncology.
    Glimelius B; Johansen C; Muren LP; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):849-51. PubMed ID: 24954366
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Brandi G; Biasco G; Tavolari S
    J Natl Cancer Inst; 2011 Aug; 103(16):1278. PubMed ID: 21775746
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.
    Bass A
    J Clin Oncol; 2011 Jul; 29(19):2728-9. PubMed ID: 21646605
    [No Abstract]   [Full Text] [Related]  

  • 7. Mutation screening for KRAS and BRAF in metastatic colorectal cancer proves costly in relation to benefits.
    Pharmacogenomics; 2013 Jan; 14(2):124. PubMed ID: 23447823
    [No Abstract]   [Full Text] [Related]  

  • 8. ONCOLOGY. Vitamin C could target some common cancers.
    Kaiser J
    Science; 2015 Nov; 350(6261):619. PubMed ID: 26542550
    [No Abstract]   [Full Text] [Related]  

  • 9. Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
    Katsios C; Ziogas DE; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):525-9. PubMed ID: 20932136
    [No Abstract]   [Full Text] [Related]  

  • 10. RAS mutations in colorectal cancer.
    Sunakawa Y; Lenz HJ; Ichikawa W
    N Engl J Med; 2013 Nov; 369(22):2159. PubMed ID: 24283233
    [No Abstract]   [Full Text] [Related]  

  • 11. RAS mutations in colorectal cancer.
    Douillard JY; Rong A; Sidhu R
    N Engl J Med; 2013 Nov; 369(22):2159-60. PubMed ID: 24283232
    [No Abstract]   [Full Text] [Related]  

  • 12. [RAS testing in metastatic colorectal cancer].
    Kirstein MM; Vogel A
    Z Gastroenterol; 2014 Sep; 52(9):1095-6. PubMed ID: 25198090
    [No Abstract]   [Full Text] [Related]  

  • 13. KRAS and BRAF mutation status in patients with sporadic colorectal cancer: data from two different Mediterranean countries.
    Symvoulakis EK; Zaravinos A; Zoras O; Spandidos DA
    Int J Biol Markers; 2011; 26(4):276-7. PubMed ID: 22139644
    [No Abstract]   [Full Text] [Related]  

  • 14. Beyond exon 2--the developing story of RAS mutations in colorectal cancer.
    Berlin J
    N Engl J Med; 2013 Sep; 369(11):1059-60. PubMed ID: 24024844
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.
    Brunner S; von Moos R; Mey U; Camenisch Gross U; Freyholdt T; Cathomas R
    Oncol Res Treat; 2014; 37(11):646-52. PubMed ID: 25427581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
    Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
    J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR signalling and oncogenic pathway signature in colorectal cancer.
    Sahin IH; Oktay AA
    Gut; 2013 Nov; 62(11):1670. PubMed ID: 23532175
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pathologic diagnosis of colorectal cancer in the era of personalized therapy].
    Lai M
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):73-6. PubMed ID: 24742564
    [No Abstract]   [Full Text] [Related]  

  • 19. The forest and the trees: pathways and proteins as colorectal cancer biomarkers.
    Bertagnolli MM
    J Clin Oncol; 2009 Dec; 27(35):5866-7. PubMed ID: 19884524
    [No Abstract]   [Full Text] [Related]  

  • 20. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies.
    Wong R; Cunningham D
    J Clin Oncol; 2008 Dec; 26(35):5668-70. PubMed ID: 19001346
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.